Your browser doesn't support javascript.
loading
IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Burotto, M; Zvirbule, Z; Mochalova, A; Runglodvatana, Y; Herraez-Baranda, L; Liu, S N; Chan, P; Shearer-Kang, E; Liu, X; Tosti, N; Zanghi, J A; Leutgeb, B; Felip, E.
Afiliación
  • Burotto M; Centro de Investigación, Clínica Bradford Hill, Santiago, Chile. Electronic address: Mburotto@bradfordhill.cl.
  • Zvirbule Z; Latvian Oncology Center, Riga Eastern Clinical University Hospital, Riga, Latvia.
  • Mochalova A; Department of Antitumor Drug Therapy, MEDSI Clinical Hospital, Moscow, Russia.
  • Runglodvatana Y; Faculty of Medicine, Vajira Hospital, Bangkok Metropolitan University, Bangkok, Thailand.
  • Herraez-Baranda L; Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Liu SN; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.
  • Chan P; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.
  • Shearer-Kang E; Product Safety Development, Genentech, Inc., South San Francisco, CA, USA.
  • Liu X; Data and Statistical Sciences, Genentech, Inc., South San Francisco, CA, USA.
  • Tosti N; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Zanghi JA; BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA.
  • Leutgeb B; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Felip E; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain; Clinical Research Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
Ann Oncol ; 34(8): 693-702, 2023 08.
Article en En | MEDLINE | ID: mdl-37268157

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article